These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 15952588)

  • 1. [Progress in renal drug targeting].
    Zheng Q; Zhang ZR
    Yao Xue Xue Bao; 2005 Mar; 40(3):199-203. PubMed ID: 15952588
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug targeting to the kidney: Advances in the active targeting of therapeutics to proximal tubular cells.
    Dolman ME; Harmsen S; Storm G; Hennink WE; Kok RJ
    Adv Drug Deliv Rev; 2010 Nov; 62(14):1344-57. PubMed ID: 20719242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineered erythrocytes as carriers and bioreactors.
    De Flora A; Tonetti M; Zocchi E; Guida L; Polvani C; Gasparini A; Benatti U
    Year Immunol; 1993; 7():168-74. PubMed ID: 8372505
    [No Abstract]   [Full Text] [Related]  

  • 4. The targeting of 14-succinate triptolide-lysozyme conjugate to proximal renal tubular epithelial cells.
    Zhang Z; Zheng Q; Han J; Gao G; Liu J; Gong T; Gu Z; Huang Y; Sun X; He Q
    Biomaterials; 2009 Mar; 30(7):1372-81. PubMed ID: 19100618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the delivery of glycan-based paclitaxel prodrugs to cancer cells via glucose transporters.
    Lin YS; Tungpradit R; Sinchaikul S; An FM; Liu DZ; Phutrakul S; Chen ST
    J Med Chem; 2008 Dec; 51(23):7428-41. PubMed ID: 19053781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles.
    Kratz F
    J Control Release; 2008 Dec; 132(3):171-83. PubMed ID: 18582981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and pharmacological effects of a cyclization-activated steroid prodrug for colon targeting in inflammatory bowel disease.
    Ruiz JF; Radics G; Windle H; Serra HO; Simplício AL; Kedziora K; Fallon PG; Kelleher DP; Gilmer JF
    J Med Chem; 2009 May; 52(10):3205-11. PubMed ID: 19397323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-molecular-weight proteins as carriers for renal drug targeting.
    Franssen EJ; Moolenaar F; de Zeeuw D; Meijer DK
    Contrib Nephrol; 1993; 101():99-103. PubMed ID: 8467694
    [No Abstract]   [Full Text] [Related]  

  • 9. [Drug delivery systems using nano-sized drug carriers].
    Nakayama M; Okano T
    Gan To Kagaku Ryoho; 2005 Jul; 32(7):935-40. PubMed ID: 16044950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In situ cross-linkable high molecular weight hyaluronan-bisphosphonate conjugate for localized delivery and cell-specific targeting: a hydrogel linked prodrug approach.
    Varghese OP; Sun W; Hilborn J; Ossipov DA
    J Am Chem Soc; 2009 Jul; 131(25):8781-3. PubMed ID: 19499915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal targeting of kinase inhibitors.
    Dolman ME; Fretz MM; Segers GJ; Lacombe M; Prakash J; Storm G; Hennink WE; Kok RJ
    Int J Pharm; 2008 Dec; 364(2):249-57. PubMed ID: 18550305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythrocyte-based drug delivery.
    Rossi L; Serafini S; Pierigé F; Antonelli A; Cerasi A; Fraternale A; Chiarantini L; Magnani M
    Expert Opin Drug Deliv; 2005 Mar; 2(2):311-22. PubMed ID: 16296756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Megalin-dependent internalization of cadmium-metallothionein and cytotoxicity in cultured renal proximal tubule cells.
    Wolff NA; Abouhamed M; Verroust PJ; Thévenod F
    J Pharmacol Exp Ther; 2006 Aug; 318(2):782-91. PubMed ID: 16690719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human renal organic anion transporters: characteristics and contributions to drug and drug metabolite excretion.
    Robertson EE; Rankin GO
    Pharmacol Ther; 2006 Mar; 109(3):399-412. PubMed ID: 16169085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Theory and methods of drug targeting].
    Hashida M
    Nihon Rinsho; 1989 Jun; 47(6):1240-8. PubMed ID: 2769985
    [No Abstract]   [Full Text] [Related]  

  • 16. Lipid nanoparticles for parenteral delivery of actives.
    Joshi MD; Müller RH
    Eur J Pharm Biopharm; 2009 Feb; 71(2):161-72. PubMed ID: 18824097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary porcine proximal tubular cells as a model for transepithelial drug transport in human kidney.
    Schlatter P; Gutmann H; Drewe J
    Eur J Pharm Sci; 2006 May; 28(1-2):141-54. PubMed ID: 16510270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size.
    Fang C; Shi B; Pei YY; Hong MH; Wu J; Chen HZ
    Eur J Pharm Sci; 2006 Jan; 27(1):27-36. PubMed ID: 16150582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha 2 mu-globulin: a model protein for studies of the renal reabsorption of low molecular weight proteins.
    Neuhaus OW
    Contrib Nephrol; 1988; 68():32-6. PubMed ID: 2466613
    [No Abstract]   [Full Text] [Related]  

  • 20. Challenges and opportunities for local and systemic delivery of siRNA and antisense oligonucleotides.
    Sepp-Lorenzino L; Ruddy M
    Clin Pharmacol Ther; 2008 Nov; 84(5):628-32. PubMed ID: 18800034
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.